A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial

Helga Hagman; Jan-Erik Frödin; Åke Berglund; Jan Sundberg; Lene Vestermark; Maria Albertsson; Eva Fernebro; Anders Johnsson

doi:10.1093/annonc/mdv490

A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial

Helga Hagman, Jan-Erik Frödin, Åke Berglund, Jan Sundberg, Lene Vestermark, Maria Albertsson, Eva Fernebro, Anders Johnsson

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	140-147
Journal	Annals of Oncology
Volume	27
Issue number	1
DOIs	https://doi.org/10.1093/annonc/mdv490
Publication status	Published - 2016 Jan
Externally published	Yes

Subject classification (UKÄ)

Cancer and Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/annonc/mdv490

1 Doctoral Thesis (compilation)

A targeted approach to maintenance of tumour response. Clinical and translational studies in metastatic colorectal cancer.
Hagman, H., 2017, Lund: Lund University: Faculty of Medicine. 127 p.
Research output: Thesis › Doctoral Thesis (compilation)

Open Access
File

Cite this

Hagman, H., Frödin, J.-E., Berglund, Å., Sundberg, J., Vestermark, L., Albertsson, M., Fernebro, E., & Johnsson, A. (2016). A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial. Annals of Oncology, 27(1), 140-147. https://doi.org/10.1093/annonc/mdv490

@article{ec3e1c14a0294ba084446f6421ef4074,

title = "A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial",

author = "Helga Hagman and Jan-Erik Fr{\"o}din and {\AA}ke Berglund and Jan Sundberg and Lene Vestermark and Maria Albertsson and Eva Fernebro and Anders Johnsson",

year = "2016",

month = jan,

doi = "10.1093/annonc/mdv490",

language = "English",

volume = "27",

pages = "140--147",

journal = "Annals of Oncology",

issn = "1569-8041",

publisher = "Oxford University Press",

number = "1",

}

Hagman, H, Frödin, J-E, Berglund, Å, Sundberg, J, Vestermark, L, Albertsson, M, Fernebro, E & Johnsson, A 2016, 'A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial', Annals of Oncology, vol. 27, no. 1, pp. 140-147. https://doi.org/10.1093/annonc/mdv490

A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial. / Hagman, Helga; Frödin, Jan-Erik; Berglund, Åke et al.
In: Annals of Oncology, Vol. 27, No. 1, 01.2016, p. 140-147.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial

AU - Hagman, Helga

AU - Frödin, Jan-Erik

AU - Berglund, Åke

AU - Sundberg, Jan

AU - Vestermark, Lene

AU - Albertsson, Maria

AU - Fernebro, Eva

AU - Johnsson, Anders

PY - 2016/1

Y1 - 2016/1

U2 - 10.1093/annonc/mdv490

DO - 10.1093/annonc/mdv490

M3 - Article

C2 - 26483047

SN - 1569-8041

VL - 27

SP - 140

EP - 147

JO - Annals of Oncology

JF - Annals of Oncology

IS - 1

ER -

A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial

Subject classification (UKÄ)

UN SDGs

Access to Document

Research output

A targeted approach to maintenance of tumour response. Clinical and translational studies in metastatic colorectal cancer.

Cite this